BioPharma Resources

Drug Trial Radar · NCT06312176

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Apr 14, 2024

Primary completion

Jul 11, 2027

Study completion Apr 12, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.

Conditions

  • Breast Neoplasms

Interventions

  • Sacituzumab tirumotecanDrug

    IV infusion

  • PembrolizumabBiological

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • Nab-paclitaxelDrug

    IV infusion

  • CapecitabineDrug

    oral tablet

  • Liposomal doxorubicinDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) ( sacituzumab tirumotecan versus treatment of physician's choice [TPC]; pembrolizumab + sacituzumab tirumotecan versus TPC)Time frame: Up to ~40 months
  2. PFS (Sacituzumab tirumotecan + pembrolizumab versus TPC)Time frame: Up to ~40 months

Locations

259 sites in 40 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Centers ( Site 0066)

    Chandler, Arizona · Recruiting

  • Banner MD Anderson Cancer Center-Oncology ( Site 0004)

    Gilbert, Arizona · Recruiting

  • Providence Medical Foundation-Oncology ( Site 0020)

    Fullerton, California · Recruiting

  • Moores Cancer Center ( Site 0059)

    La Jolla, California · Active not recruiting

  • Cancer and Blood Specialty Clinic ( Site 0001)

    Los Alamitos, California · Active not recruiting

  • University of Colorado Anschutz Medical Campus ( Site 0061)

    Aurora, Colorado · Recruiting

  • UCHealth Cherry Creek Medical Center ( Site 0094)

    Denver, Colorado · Recruiting

  • University of Colorado Health - Highlands Ranch Hospital ( Site 0095)

    Highlands Ranch, Colorado · Completed

  • Yale Cancer Center ( Site 0060)

    New Haven, Connecticut · Active not recruiting

  • Stamford Hospital ( Site 0049)

    Stamford, Connecticut · Recruiting

  • AdventHealth Altamonte Springs ( Site 0021)

    Altamonte Springs, Florida · Recruiting

  • University of Florida College of Medicine ( Site 0063)

    Gainesville, Florida · Active not recruiting

  • Orlando Health Cancer Institute ( Site 0011)

    Orlando, Florida · Recruiting

  • Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032)

    Thomasville, Georgia · Completed

  • Rush University Medical Center ( Site 0079)

    Chicago, Illinois · Recruiting

  • University of Chicago Medical Center ( Site 0067)

    Chicago, Illinois · Active not recruiting

  • Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0053)

    Edgewood, Kentucky · Recruiting

  • Mary Bird Perkins Cancer Center-Breast & GYN Pavilion ( Site 0042)

    Baton Rouge, Louisiana · Recruiting

  • Greenebaum Comprehensive Cancer Center ( Site 0036)

    Baltimore, Maryland · Recruiting

  • Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0028)

    Baltimore, Maryland · Completed

  • Holy Cross Hospital ( Site 0073)

    Silver Spring, Maryland · Recruiting

  • Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037)

    Boston, Massachusetts · Recruiting

  • Henry Ford Health ( Site 0002)

    Detroit, Michigan · Recruiting

  • Saint Luke's Cancer Institute ( Site 0027)

    Kansas City, Missouri · Recruiting

  • Washington University School of Medicine ( Site 0076)

    St Louis, Missouri · Recruiting

  • NYU Langone Health - Brooklyn ( Site 0089)

    Brooklyn, New York · Recruiting

  • NYU Langone Hospital - Long Island ( Site 0090)

    Mineola, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0068)

    New York, New York · Recruiting

  • Hematology Oncology Associates of Rockland ( Site 0054)

    Nyack, New York · Recruiting

  • Stony Brook University-Cancer Center ( Site 0034)

    Stony Brook, New York · Recruiting

  • Levine Cancer Institute ( Site 0014)

    Charlotte, North Carolina · Recruiting

  • Zangmeister Cancer Center ( Site 7000)

    Columbus, Ohio · Completed

  • Providence Portland Medical Center ( Site 0044)

    Portland, Oregon · Recruiting

  • Providence St. Vincent Medical Center ( Site 0081)

    Portland, Oregon · Recruiting

  • Thomas Jefferson University - Clinical Research Institute ( Site 0056)

    Philadelphia, Pennsylvania · Recruiting

  • Texas Oncology-Dallas Presbyterian Hospital ( Site 8000)

    Dallas, Texas · Recruiting

  • Parkland Health and Hospital System ( Site 0069)

    Dallas, Texas · Recruiting

  • UT Southwestern Medical Center ( Site 0050)

    Dallas, Texas · Recruiting

  • The Center for Cancer and Blood Disorders ( Site 0041)

    Fort Worth, Texas · Recruiting

  • Texas Oncology - San Antonio ( Site 8002)

    San Antonio, Texas · Recruiting

Showing 40 of 259 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.